Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief Commercial Officer, MRD | August 07, 2023 | August 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date August 07, 2023 · Filed August 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 214,808 |
Ending reported balance
After 2023-08-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-08-07 · Sale · Disposed 5,652 · Balance 225,358 F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Row 2 · 2023-08-08 · Sale · Disposed 10,550 · Balance 214,808 F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $6.48 to $6.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022.
F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $6.48 to $6.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 08, 2023 Filed Aug 8, 2023 16:53 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,550 | $6.54 | $68,997.00 |
DisclosureSEC source: 0001062993-23-016018 · form4.xml · nonDerivative · entry 2 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,808 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $6.48 to $6.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 16:53 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,652 | $6.78 | $38,320.56 |
DisclosureSEC source: 0001062993-23-016018 · form4.xml · nonDerivative · entry 1 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,358 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 20:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 9,813 | $8.60 | $84,391.80 |
DisclosureSEC source: 0001062993-23-006324 · form4.xml · nonDerivative · entry 3 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,010 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.25 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 20:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 199,549 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001062993-23-006324 · form4.xml · derivative · entry 4 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,549 Underlying: Common Stock · 199,549 shares Expires 2033-03-06 F4 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 20:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,661 | $8.57 | $57,084.77 |
DisclosureSEC source: 0001062993-23-006324 · form4.xml · nonDerivative · entry 2 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,823 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 20:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 132,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006324 · form4.xml · nonDerivative · entry 1 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,484 Read SEC document |
| November 01, 2022 Filed Nov 1, 2022 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 31,066 | $8.00 | $248,528.00 |
DisclosureSEC source: 0001209191-22-055170 · doc4.xml · nonDerivative · entry 1 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,505 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. Read SEC document |
| August 05, 2022 Filed Aug 5, 2022 20:49 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 17,540 | $10.98 | $192,589.20 |
DisclosureSEC source: 0001209191-22-044688 · doc4.xml · nonDerivative · entry 1 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,571 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 164,745 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017400 · doc4.xml · derivative · entry 2 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,745 Underlying: Common Stock · 164,745 shares Expires 2032-03-04 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 65,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017400 · doc4.xml · nonDerivative · entry 1 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,111 Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 18:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 162,022 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001209191-21-052344 · doc4.xml · derivative · entry 2 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,022 Underlying: Common Stock · 162,022 shares Expires 2031-08-16 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on August 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 18:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 97,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-052344 · doc4.xml · nonDerivative · entry 1 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,213 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.